Biohaven Ltd. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Biohaven announced two major partnerships: (1) SK Biopharmaceuticals acquired exclusive global rights to Kv7 platform including opakalim (BHV-7000) for $400M ($350M at closing, $50M in year 1) plus up to $150M in milestones and tiered royalties; (2) Ono Pharmaceutical licensed MoDE IgG degrader portfolio for Japan/Korea/Taiwan/ASEAN regions for up to $100M ($80M upfront received, $20M milestone). Offsetting: FDA imposed partial clinical hold on opakalim new enrollment in September 2026 due to uncertain metabolite safety signals in rodents; RISE 3 topline data (fully enrolled) remains on track for H2 2026. Company reported Q3 2026 net loss of $129.3M on $164M cash position (pre-licensing cash).
Why this rating
Two transformational partnerships worth $430M in near-term cash (43% of market cap) substantially extend runway and validate platforms. Clinical hold is contained to new enrollment, not ongoing dosing. Material event relative to company size.
Price action (we called it positive)
before filing · preread $16.17 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.